BWAY vs. ALUR, NVNO, MGRM, BLUA, KRMD, PDEX, SEPA, AMIX, SRTS, and ICCM
Should you be buying BrainsWay stock or one of its competitors? The main competitors of BrainsWay include Allurion Technologies (ALUR), enVVeno Medical (NVNO), Monogram Orthopaedics (MGRM), BlueRiver Acquisition (BLUA), KORU Medical Systems (KRMD), Pro-Dex (PDEX), SEP Acquisition (SEPA), Autonomix Medical (AMIX), Sensus Healthcare (SRTS), and IceCure Medical (ICCM). These companies are all part of the "surgical & medical instruments" industry.
Allurion Technologies (NYSE:ALUR) and BrainsWay (NASDAQ:BWAY) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, profitability, community ranking, institutional ownership, dividends and earnings.
In the previous week, BrainsWay had 1 more articles in the media than Allurion Technologies. MarketBeat recorded 2 mentions for BrainsWay and 1 mentions for Allurion Technologies. BrainsWay's average media sentiment score of 0.66 beat Allurion Technologies' score of 0.54 indicating that Allurion Technologies is being referred to more favorably in the media.
Allurion Technologies presently has a consensus price target of $5.00, indicating a potential upside of 170.27%. BrainsWay has a consensus price target of $7.00, indicating a potential upside of 39.17%. Given BrainsWay's stronger consensus rating and higher probable upside, analysts plainly believe Allurion Technologies is more favorable than BrainsWay.
Allurion Technologies has a beta of -0.03, indicating that its stock price is 103% less volatile than the S&P 500. Comparatively, BrainsWay has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500.
Allurion Technologies has a net margin of 0.00% compared to Allurion Technologies' net margin of -13.20%. BrainsWay's return on equity of 0.00% beat Allurion Technologies' return on equity.
BrainsWay has lower revenue, but higher earnings than Allurion Technologies.
21.4% of Allurion Technologies shares are owned by institutional investors. Comparatively, 30.1% of BrainsWay shares are owned by institutional investors. 20.0% of Allurion Technologies shares are owned by insiders. Comparatively, 19.0% of BrainsWay shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
BrainsWay received 58 more outperform votes than Allurion Technologies when rated by MarketBeat users. However, 100.00% of users gave Allurion Technologies an outperform vote while only 63.83% of users gave BrainsWay an outperform vote.
Summary
Allurion Technologies beats BrainsWay on 8 of the 15 factors compared between the two stocks.
Get BrainsWay News Delivered to You Automatically
Sign up to receive the latest news and ratings for BWAY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BWAY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BrainsWay Competitors List
Related Companies and Tools
